唐晓辉, 陈南星, 刘唐轶赫, 肖莉萍, 贾贤杰, 于影. 阿加曲班治疗超出溶栓时间窗缺血性脑卒中的临床研究[J]. 蚌埠医学院学报, 2023, 48(11): 1534-1536. DOI: 10.13898/j.cnki.issn.1000-2200.2023.11.011
    引用本文: 唐晓辉, 陈南星, 刘唐轶赫, 肖莉萍, 贾贤杰, 于影. 阿加曲班治疗超出溶栓时间窗缺血性脑卒中的临床研究[J]. 蚌埠医学院学报, 2023, 48(11): 1534-1536. DOI: 10.13898/j.cnki.issn.1000-2200.2023.11.011
    TANG Xiao-hui, CHEN Nan-xing, LIU Tang-yi-he, XIAO Li-ping, JIA Xian-jie, YU Ying. Clinical study of argatroban in the treatment of ischemic stroke beyond thrombolysis time window[J]. Journal of Bengbu Medical College, 2023, 48(11): 1534-1536. DOI: 10.13898/j.cnki.issn.1000-2200.2023.11.011
    Citation: TANG Xiao-hui, CHEN Nan-xing, LIU Tang-yi-he, XIAO Li-ping, JIA Xian-jie, YU Ying. Clinical study of argatroban in the treatment of ischemic stroke beyond thrombolysis time window[J]. Journal of Bengbu Medical College, 2023, 48(11): 1534-1536. DOI: 10.13898/j.cnki.issn.1000-2200.2023.11.011

    阿加曲班治疗超出溶栓时间窗缺血性脑卒中的临床研究

    Clinical study of argatroban in the treatment of ischemic stroke beyond thrombolysis time window

    • 摘要:
      目的探讨阿加曲班在超出溶栓时间窗缺血性脑卒中治疗中的应用价值。
      方法选择超过溶栓时间窗的缺血性脑卒中病人86例,随机分为对照组46例和观察组40例。对照组病人实施常规抗栓治疗,轻型卒中给予阿司匹林联合氯吡格雷,21 d后改为阿司匹林继续治疗,非轻型给予阿司匹林治疗;观察组病人采用阿加曲班联合阿司匹林治疗。比较2组病人美国国立卫生研究院卒中量表(NIHSS)评分和改良Rankin量表(mRS)评分。
      结果观察组出院当天、出院1个月NIHSS评分均低于对照组(P < 0.05);观察组入院当天、出院当天、出院1个月NIHSS评分逐渐降低(P < 0.05);对照组入院当天、出院当天、出院1个月NIHSS评分差异无统计学意义(P>0.05)。观察组出院当天、出院1个月mRS评分均低于对照组(P < 0.05);观察组入院当天、出院当天及出院1个月mRS评分逐渐降低(P < 0.05);对照组入院当天、出院当天及出院1个月mRS评分差异无统计学意义(P < 0.05)。
      结论阿加曲班治疗超出溶栓时间窗缺血性脑卒中效果显著,有利于改善病人预后,安全性良好。

       

      Abstract:
      ObjectiveTo investigate the application value of argatroban in the treatment of ischemic stroke beyond thrombolysis time window.
      MethodsEighty-six patients with ischemic stroke beyond thrombolysis time window were selected, and randomly divided into the control group (n=46) and observation group (n=40).The patients in the control group were treated with routine antithrombotic therapy, the patients with minor stroke were treated with aspirin combined with clopidogrel, and the treatment was changed to aspirin after 21 days, while patients with non-minor stroke were treated with aspirin.The patients in the observation group were treated with argatroban combined with aspirin.The National Institutes of Health stroke scale (NIHSS) score and the modified Rankin scale (mRS) score were compared between the two groups.
      ResultsThe NIHSS scores in the observation group on the day of discharge and one month after discharge were lower than those in the control group (P < 0.05);the NIHSS scores in the observation group decreased gradually on the day of admission, the day of discharge and one month after discharge (P < 0.05);the difference of NIHSS scores in the control group among the day of admission, the day of discharge and one month after discharge was not statistically significant (P>0.05).The mRS scores in the observation group on the day of discharge and one month after discharge were lower than those in the control group (P < 0.05);the mRS scores in the observation group decreased gradually on the day of admission, the day of discharge and one month after discharge (P < 0.05);the difference of mRS scores in the control group among the day of admission, the day of discharge and one month after discharge was not statistically significant(P>0.05).
      ConclusionsArgatroban is effective in the treatment of ischemic stroke beyond thrombolytic time window, is beneficial to improve the prognosis of patients, and has good safety.

       

    /

    返回文章
    返回